Worldwide, the syndromes of paraganglioma (PGL), somatostatinoma (SOM) and early childhood polycythemia are described in only a few patients with somatic mutations in the hypoxia-inducible factor 2 alpha (HIF2A). This study provides detailed information about the clinical aspects and course of 7 patients with this syndrome and brings
Introduction
Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are rare catecholamine-producing neuroendocrine tumors (NETs) arising in or outside the adrenal medulla, respectively (Lenders et al. 2005) . By definition, a PHEO is an intra-adrenal PGL. To date, it has been recognized that up to 35-40% of these tumors are hereditary, with about 19 causally linked mutated genes (Crona et al. 2013 , Pacak & Wimalawansa 2015 . Among these genes, much attention has been directed to those affecting hypoxiasignaling pathways because many of the associated tumors express a so-called 'pseudohypoxic signature' and most of them converge on the hypoxia-signaling pathway .
Germline mutations in the von Hippel-Lindau (VHL) gene trigger overexpression of hypoxia-inducible factor (HIF) proteins and cause VHL disease, which may predispose to various tumors such as multiple PHEOs/ PGLs, hemangioblastomas of the retina and central nervous system, as well as kidney cysts, renal cell carcinoma and polycythemia, among others (Haase 2009 , Taïeb et al. 2016 . Mutations in another HIF-regulating protein gene, prolyl hydroxylase domain protein 2 (PHD2) and, more recently, PHD1, which hydroxylate HIF and enable its VHL-mediated degradation, have been associated with secondary polycythemia and multiple PGLs . Nevertheless, the occurrence of PGL together with polycythemia is rare (Dionne et al. 2006) . Somatic mutations in HIF2A (EPAS1), affecting PHD hydroxylation and subsequent VHL degradation, were recently recognized to cause a syndrome consisting of PGL and/or somatostatinoma (SOM) associated with polycythemia in females (Zhuang et al. 2012 ). Since then, more patients with the syndrome have been described carrying the mutations in this gene. Nevertheless, at present, the triad of PGL, SOM and polycythemia has been exclusively found in females. Furthermore, normal tissues genomic DNA mosaicism of HIF2A mutations has recently been detected in two out of four initial patients specifically presenting with this syndrome (Yang et al. 2015) .
The clinical dyad/triad of PGLs and/or SOMs associated with polycythemia, also referred to as 'Pacak-Zhuang syndrome' (Toyoda et al. 2014) , may be regarded as a new tumor syndrome, similar to multiple endocrine neoplasia (MEN) syndromes, VHL disease, Carney-Stratakis syndrome, Carney triad, Cowden syndrome or the PHEO-PGL syndrome, among others (Gaal & de Krijger 2010 , Ni et al. 2012 . From the first studies published by our group, additional new clinical phenotypes have been identified through the follow-up of previously described and newly diagnosed patients with this syndrome.
In this study, we provide detailed clinical information on 7 patients with the PGL, SOM and polycythemia syndrome carrying the somatic HIF2A mutation, including Endocrine-Related Cancer (2016) 23, 899-908 a teenage boy, diagnosed and followed at the NIH for 6 years. New clinical information particularly pertains to aspects of genetics, tumor imaging, organ involvement, disease progression and patient outcomes. We also searched the literature for studies and reports on related tumor syndromes and diseases with activating mutations of the HIF2A gene and discuss our findings in the context of this other data. As a result, we propose strategies for diagnosis and therapy of patients with PGL, SOM and polycythemia syndrome.
Materials and methods

Patient evaluation
Patients were evaluated under protocol (00-CH-0093) approved by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Institutional Review Board. All patients provided written informed consent. We carefully reviewed all patients' demographics, clinical manifestations, biochemical and hematological profiles, radiographic findings and outcomes based on frequent follow-ups and very close interactions with outside physicians (Supplementary Table 1 , see section on supplementary data given at the end of this article).
Laboratory analyses
All laboratory analyses, mutation analysis, hydroxylation assays, real-time polymerase chain reaction and chromatin immunoprecipitation were performed, as described previously .
Imaging studies
Anatomical imaging using computed tomography (CT) and magnetic resonance imaging (MRI) of the neck, chest, abdomen and pelvis were performed as described previously, along with positron emission tomography (PET)/CT studies using (Janssen et al. 2015) . In addition, CT scans with negative enteric contrast were used to better detect duodenal tumors, as performed in our previous studies .
Results
Gender, mutation status with evidence of mosaicism of HIF2A, ages at the latest outpatient visit and ages at diagnosis of polycythemia; occurrence of PHEO/PGL, SOM and number of lesions; recurrence of lesions, as well as surgical and other treatment modalities for individual patients in chronological order are shown in Fig. 1 . None of the family members had any history of polycythemia, PHEO/PGL or SOM. Detailed clinical presentations are described in Supplementary Table 1. Patients received regular follow-up at the NIH for a median of 6 years (range 1-11) since their first tumor resection. The median age of patients at the time of their last follow-up at the NIH was 28 years (range 11-46).
Polycythemia was detected in patients in early childhood (median 2 years, range from birth to 7 years). 
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Erythropoietin (EPO) levels were an average of 5 times above the upper limit of normal in all patients. For patient No. 3, EPO levels are plotted together with levels of hemoglobin and hematocrit over the course of the patient's visits at the NIH (Fig. 2) . There was no longterm normalization of EPO levels even after surgery in any patient.
PGL developed later in life at a median age of 17 years (range 8-38) in all patients. PGLs were predominantly of the norepinephrine-producing biochemical phenotype. After surgery, levels of normetanephrine dropped significantly (not shown). Patients were found to have multiple (100%), recurrent (100%) and metastatic (29%) PGLs, with adrenal involvement in four cases.
Five of 7 patients had a manifestation of SOM at a median of 29 years (range 22-38) . No patient was found to have SOM diagnosed before the occurrence of PGL. Patient No. 5, an 11-year-old girl, and No. 7, a 17-year-old boy have not yet developed SOM. SOM was confirmed either histologically or biochemically. In the case of patient No. 4, the diagnosis of SOM was In four patients, we had histological proof of SOM. We found solitary (40%), multiple (40%), recurrent (40%) and metastatic SOMs in 3 cases (60%). All patients with SOM were diagnosed with gallbladder disease, with four having chronic cholecystitis and two, cholelithiasis, usually in early adulthood at a median of 29 years (range 19-39). Two patients, No. 3 and 6, were diagnosed with noninsulin-dependent diabetes at the ages of 26 and 38, respectively, which may be regarded as manifestation of PGL (Lenders et al. 2005) , and which resolved in patient No. 3 after her second surgery (Supplementary Table 1 ).
All patients received an ophthalmology consultation because of known ocular complications occurring with this syndrome (Pacak et al. 2014) . The results are summarized in Table 1 . We observed optic disc fibrosis in all patients ( Supplementary Fig. 1 ). Three patients had macular changes and three peripheral retinal changes. For patient No. 5, ophthalmologic changes were noticed even before polycythemia was diagnosed and before the occurrence of PGL.
Anatomical and functional imaging characteristics are summarized in Table 2 . On anatomical imaging, we found cystic lesions in 4 out of 7 patients. Cysts were localized to the kidneys, breasts, lungs, pericardium, cervix and pancreas. Because the pancreatic cyst of patient No. 6 developed in the interval between two surgeries and was fading to disappearance on imaging over the course of several months, there is the possibility that this cyst was iatrogenically induced by the first surgery. Patients also presented with adnexal cysts but, because of time-dependent changes, these were regarded as physiological or not part of the cystic lesions related to the syndrome. For instance, patient No. 3 had been diagnosed with polycystic ovary syndrome (PCOS) in the past and we could identify a persisting pelvic cyst on MRI, patient No. 4 had an enlarged ovarian cyst (30 × 28 mm) at the age of 11, and patient No. 6 had been operated on for polycystic ovaries at the age of 31.
An overview of the current literature on patients with HIF2A gain-of-function mutations and a summary of pertinent information about the position and type of mutations, presence of mosaicism, mode of inheritance, phenotypic expression and gender distribution are given in Supplementary Table 3. Apart from the 7 patients described in the present investigation, 56 additional patients with activating HIF2A mutations were identified in prior published studies and reports between the years 2008 and 2016: one additional female patient with Pacak-Zhuang syndrome, 7 patients (3 females, 4 males) with polycythemia and PHEO/PGL but without SOM, 16 patients (12 females, 2 males) with PHEO/ PGL including 2 females with gangliocytic PGL (GPGL) without polycythemia or SOM, 2 patients (1 female, 1 male) with central nervous system hemangioblastomas without polycythemia, PHEO/PGL or SOM, and 28 patients (15 females, 12 males, no record of gender in 1) with isolated sporadic or familial polycythemia plus one female offspring with inherited HIF2A mutation, but without polycythemia. One other female patient without any signs of organic disease was found to be a carrier of an activating HIF2A mutation, which she passed to her 50-year-old son who had polycythemia and PHEO/PGL. There was a remarkable partial overlap of position and type of mutations among patients with PHEO/PGL with or without polycythemia, and patients with Pacak-Zhuang syndrome. Identical mutations were also described in patients with isolated sporadic and familial polycythemia. However, there was no overlap of mutations in these latter two groups of patients compared with the former, indicating mutation-specific fundamental differences in downstream signaling pathways of HIF2A leading to either isolated polycythemia or PHEO/PGL with or without polycythemia or PacakZhuang syndrome.
Discussion
This report provides comprehensive new information on a 6-year follow-up of 7 patients carrying activating somatic HIF2A mutations who presented with the syndrome of PGL or SOM associated with polycythemia (Pacak-Zhuang syndrome) , and brings these experiences into perspective with the pertinent literature. The involvement of the downstream HIF2A signaling pathway in the pathophysiology of this new syndrome is strongly supported by its association with distinct HIF2A mutations as well as by the occurrence of closely related clinical phenotypes described in some reports of patients with VHL syndrome (Karasawa et al. 2001 , Haase 2009 ), and of polycythemia and PGL in patients with mutated PHD1 and PHD2 .
As a hallmark of the syndrome in all of our patients, polycythemia was diagnosed either at birth or in early childhood, and always before PHEO/PGL and SOM, which is typically discovered after the development of PHEO/ PGL. All patients were found to have eye involvement at manifestation of the disease (Pacak et al. 2014) . Furthermore, EPO levels were elevated in all patients and did not return to normal after surgical tumor removal, making paraneoplastic EPO production less likely. Mosaicism with HIF2A gain-of-function mutations in EPO-producing renal interstitial cells or hepatocytes (Haase 2013) leading to continuous stimulation of EPO synthesis may be a reasonable alternative explanation. Although, in our series, mosaicism was only found in two patients (Patients No. 1 and 3; see also Yang et al. 2015) . On the other hand, there is evidence from studies in patients with familial or sporadic polycythemia harboring HIF2A gain-of-function mutations to suggest that polycythemia does not necessarily rely on increased EPO (Martini et al. 2008 , Gale et al. 2008 , Percy et al. 2008a 
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2009, van Wijk et al. 2010 , Percy et al. 2012 , Perrotta et al. 2013 , Alaikov et al. 2016 , indicating that the link between polycythemia and EPO in patients with this syndrome may be less direct than intuitively expected. Other genetic abnormalities, including the timing of when HIF2A mutations occur, may further contribute to the full spectrum of this disease as in other hereditary syndromes.
In our patients, PHEOs/PGLs were detected at a median age of 17 years, some 15 years after the diagnosis of polycythemia, and similar time intervals have been reported in other studies on patients with this syndrome with or without established SOMs (Comino-Mendez et al. 2013 , Taïeb et al. 2013 , Buffet et al. 2014 , Toyoda et al. 2014 , as well as in one patient with familial polycythemia and PGL (Lorenzo et al. 2013) . Together, these observations are in support of the concept that activating HIF2A mutations predispose to, but may not be sufficient for, the development of PHEOs/PGLs (Lorenzo et al. 2013) . Of note, sporadic PHEOs/PGLs and other solid tumors with activating somatic HIF2A mutations occurring in the adult age do not appear to be preceded or accompanied by polycythemia, despite largely overlapping genetic changes compared with patients with Pacak-Zhuang syndrome or familial polycythemia with PHEO/PGL (Favier et al. 2012 , Comino-Mendez et al. 2013 , Toledo et al. 2013 , Welander et al. 2014 , Taïeb et al. 2016 , Zhuang et al. 2016 . It is therefore conceivable that patients with Pacak-Zhuang syndrome and familial polycythemia with PHEO/PGL may harbor additional, yet unidentified tumor-promoting aberrations, which are not present in sporadic PHEOs/ PGLs later in life, the most obvious phenotypic reflections of which are polycythemia and increased EPO. Another explanation may be due to the precise timing of when an activating HIF2A mutation occurs during embryogenesis. It is anticipated that deep sequencing may allow a more definitive answer.
Considerations such as the above may also explain the distinct clinical features of SOMs in the patients described in this study and by others (Buffet et al. 2014) , which resemble those seen in conjunction with hereditary tumor syndromes, specifically neurofibromatosis type 1 (von Recklinghausen disease-NF1), MEN type 1 and VHL disease. Similarities include a median age of onset of which is nearly two decades earlier (at 29 years), a lower rate of malignancy (despite early metastases in regional lymph nodes), and the preferential duodenal localization compared with sporadic SOMs (Klöppel et al. 2004 , Marini et al. 2009 , with the notable exception of VHL disease, where SOMs are predominantly found in the pancreas (Hammel et al. 2000) . However, sporadic SOMs and SOMs associated with NF1, MEN1 or VHL gene mutations are clearly distinguished from SOMs in patients with this syndrome by their substantially lower incidence and equal gender distribution. Therefore, even assuming the presence of an acquired genetic predisposition, the observation of a highly efficient and exclusive expression of SOMs in women remains a puzzling feature of this syndrome.
Tumor location and biochemical phenotype of our patients fit well into the entity of 'pseudohypoxic' cluster 1 tumors, as is the case for VHL, PHD and for patients harboring succinate dehydrogenase (SDHx) mutations (Eisenhofer et al. 2011 , Richter et al. 2013 . As in these patients (Neumann et al. 2002) , HIF2A gain-of-function mutations may manifest with head and neck PGL. This was the case in patient No. 2 with an undefined skull-based lesion (Fig. 3) .
Patients with SDHB mutations are especially prone to malignant diseases (Gimenez-Roqueplo et al. 2003) . In contrast, expression of tumor-promoting genes seems to be less pronounced in patients with activating HIF2A mutations (Favier et al. 2012) , resulting in a less aggressive PHEO/PGL phenotype. Indeed, none of our patients with metastatic PGLs thus far required chemotherapy or repeated radiotherapy, and none have died even 11 years after the first surgery. Therefore, these patients can be reassured that their overall outlook is favorable, although recurrent disease at multiple sites is highly probable and will require repeated surgeries, beginning at a young age.
The best functional imaging tracer for localization of tumors within this syndrome in our series was [ 18 F]-FDOPA, and in line with recent recommendations for localization of NETs with a low Ki-67 Index (van Essen et al. 2014 (Timmers et al. 2007 , 2009 , Janssen et al. 2015 . The demonstration of cystic and hemangiomatous lesions in all of our patients but the two teenage subjects suggests shared phenotypic features in patients harboring mutated VHL (Haase 2009 , Taïeb et al. 2016 .
Although limited by a small number of patients in this case series, our findings call for several recommendations (Neumann & Eng 2009 ): (a) consider genetic testing
for HIF2A mutations in congenital polycythemia; (b) screen for PHEO/PGL starting from the age of about eight; (c) perform yearly measurement of plasma or urine metanephrines; (d) perform regular (every 1-2 years) whole-body or at least abdominal imaging, MRI in children; (e) consider a surgical approach as no specific therapies are currently known; (f) PGLs are predominantly norepinephrine-producing and, therefore, patients should preferably be on an α-adrenoceptor blockade; (g) screen for SOM starting from about the age of 20; (h) measure somatostatin levels in all patients with HIF2A mutations; (i) in all SOMs larger than 1 cm metastatic potential is high and, therefore, attempt early endoscopic or surgical removal; (j) use a negative enteric contrast CT scan or endoscopic examination for SOMs; (k) base follow-up for SOMs on the measurement of plasma somatostatin levels and imaging; (l) search for other, especially gastrin-but also other neurohormone-secreting NETs.
In summary, we present the most updated follow-up of 7 patients with HIF2A mutations and Pacak-Zhuang syndrome consisting of PHEO/PGL or SOM associated with polycythemia, and discuss these experiences in the context of the pertinent literature. We conclude that due to its multifaceted manifestations an interdisciplinary approach to the patient with this syndrome is imperative in order to allow for the best possible outcome. Current treatment options are exclusively surgical.
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